Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49,883,741
-
Total 13F shares
-
3,242,041
-
Share change
-
+466,471
-
Total reported value
-
$22,632,114
-
Price per share
-
$6.98
-
Number of holders
-
21
-
Value change
-
+$3,357,911
-
Number of buys
-
10
-
Number of sells
-
10
Institutional Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q4 2025
As of 31 Dec 2025,
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,242,041 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Wealthcare Advisory Partners LLC, CWA Asset Management Group, LLC, GOLDMAN SACHS GROUP INC, Bank of New York Mellon Corp, WHITE PINE CAPITAL LLC, DEUTSCHE BANK AG\, Cambridge Investment Research Advisors, Inc., and JPMORGAN CHASE & CO.
This page lists
22
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.